SHPMY Revenue

Shanghai Pharmaceuticals Holding had revenue of 73.48B CNY in the quarter ending September 30, 2025, with 4.65% growth. This brings the company's revenue in the last twelve months to 280.69B, up 3.04% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.

Revenue (ttm)

280.69B CNY

Revenue Growth

+3.04%

P/S Ratio

0.21

Revenue / Employee

5.60M CNY

Employees

50,120

Market Cap

8.33B USD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	275.25B	14.96B	5.75%
Dec 31, 2023	260.30B	28.31B	12.21%
Dec 31, 2022	231.98B	16.16B	7.49%
Dec 31, 2021	215.82B	23.92B	12.46%
Dec 31, 2020	191.91B	5.34B	2.86%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2016	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2015	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Zynex	108.20M
China Medicine	65.76M
PD-Rx Pharmaceuticals	18.35M
Exlites Holdings International	9.42M
Pharmagen	4.41M
Gold Enterprise Group	559.55K
Global Medical Products Holdings	45.96K
DH Enchantment	-42.87K

Revenue Rankings

Shanghai Pharmaceuticals Holding News

1 year ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
1 year ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha

More News